Skip to main content

Table 1 Patient and tumor characteristics

From: SPARC expression in patients with high-risk localized soft tissue sarcoma treated on a randomized phase II trial of neo/adjuvant chemotherapy

 

Primary tumor (n = 50)

Recurrent tumor (n = 17)

Sex

 Male

34

12

 Female

16

5

Median age in years (range)

61 (19–76)

50 (19–66)

Site of primary disease

 Extremity

30

10

 Trunk

19

7

 Head & Neck

1

0

Site of recurrent disease

NA

 

 Local

8

 Distant

9

Histology

 Undifferentiated pleomorphic sarcoma (UPS)

32

6

 Leiomyosarcoma (LMS)

6

1

 Liposarcoma (LPS)

6

1

 Synovial sarcoma (SS)

3

4

 Malignant peripheral nerve sheath tumor (MPNST)

2

3

 Fibrosarcoma (FS)

1

2

Prior treatment

 Gemcitabine/docetaxel

27

2

 Doxorubicin/ifosfamide

17

1

 Doxorubicin/dacarbazine

0

1

 None

7

13

 Radiation

2

0